{"id":29654,"date":"2024-04-08T08:12:35","date_gmt":"2024-04-08T07:12:35","guid":{"rendered":"https:\/\/www.curiumpharma.com\/?p=29654"},"modified":"2024-06-18T11:20:54","modified_gmt":"2024-06-18T10:20:54","slug":"acquisition-agreement","status":"publish","type":"post","link":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/","title":{"rendered":"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":89,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[99],"tags":[119,109,132,110],"class_list":["post-29654","post","type-post","status-publish","format-standard","hentry","category-press-releases-de","tag-news-de","tag-nuclear-medicine-de","tag-pet-de","tag-prl-de"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol - Curium Pharma<\/title>\n<meta name=\"description\" content=\"Curium to expand Lutetium-177 capacity and PET footprint with Eczac\u0131ba\u015f\u0131-Monrol acquisition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol - Curium Pharma\" \/>\n<meta property=\"og:description\" content=\"Curium to expand Lutetium-177 capacity and PET footprint with Eczac\u0131ba\u015f\u0131-Monrol acquisition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Curium Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-08T07:12:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-18T10:20:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2018\/05\/Curium-Logo.jpg\" \/>\n<meta name=\"author\" content=\"Elisabeth Baucells\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2019\/04\/Curium-Logo-01-with-transparent-bckgrnd-w-tagline-1-2000x892.png\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elisabeth Baucells\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/\"},\"author\":{\"name\":\"Elisabeth Baucells\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/e4f8faf9cb0b0abf9a175f21afe353c6\"},\"headline\":\"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol\",\"datePublished\":\"2024-04-08T07:12:35+00:00\",\"dateModified\":\"2024-06-18T10:20:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/\"},\"wordCount\":16,\"keywords\":[\"news\",\"Nuclear medicine\",\"PET\",\"PRL\"],\"articleSection\":[\"Pressemeldungen\"],\"inLanguage\":\"de-DE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/\",\"name\":\"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol - Curium Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\"},\"datePublished\":\"2024-04-08T07:12:35+00:00\",\"dateModified\":\"2024-06-18T10:20:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/e4f8faf9cb0b0abf9a175f21afe353c6\"},\"description\":\"Curium to expand Lutetium-177 capacity and PET footprint with Eczac\u0131ba\u015f\u0131-Monrol acquisition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/2024\\\/04\\\/08\\\/acquisition-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/\",\"name\":\"Curium Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curiumpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curiumpharma.com\\\/#\\\/schema\\\/person\\\/e4f8faf9cb0b0abf9a175f21afe353c6\",\"name\":\"Elisabeth Baucells\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g\",\"caption\":\"Elisabeth Baucells\"},\"url\":\"https:\\\/\\\/www.curiumpharma.com\\\/de\\\/author\\\/elisabeth-baucellscuriumpharma-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol - Curium Pharma","description":"Curium to expand Lutetium-177 capacity and PET footprint with Eczac\u0131ba\u015f\u0131-Monrol acquisition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/","og_locale":"de_DE","og_type":"article","og_title":"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol - Curium Pharma","og_description":"Curium to expand Lutetium-177 capacity and PET footprint with Eczac\u0131ba\u015f\u0131-Monrol acquisition.","og_url":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/","og_site_name":"Curium Pharma","article_published_time":"2024-04-08T07:12:35+00:00","article_modified_time":"2024-06-18T10:20:54+00:00","og_image":[{"url":"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2018\/05\/Curium-Logo.jpg","type":"","width":"","height":""}],"author":"Elisabeth Baucells","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.curiumpharma.com\/wp-content\/uploads\/2019\/04\/Curium-Logo-01-with-transparent-bckgrnd-w-tagline-1-2000x892.png","twitter_misc":{"Verfasst von":"Elisabeth Baucells"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/#article","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/"},"author":{"name":"Elisabeth Baucells","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/e4f8faf9cb0b0abf9a175f21afe353c6"},"headline":"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol","datePublished":"2024-04-08T07:12:35+00:00","dateModified":"2024-06-18T10:20:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/"},"wordCount":16,"keywords":["news","Nuclear medicine","PET","PRL"],"articleSection":["Pressemeldungen"],"inLanguage":"de-DE"},{"@type":"WebPage","@id":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/","url":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/","name":"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol - Curium Pharma","isPartOf":{"@id":"https:\/\/www.curiumpharma.com\/#website"},"datePublished":"2024-04-08T07:12:35+00:00","dateModified":"2024-06-18T10:20:54+00:00","author":{"@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/e4f8faf9cb0b0abf9a175f21afe353c6"},"description":"Curium to expand Lutetium-177 capacity and PET footprint with Eczac\u0131ba\u015f\u0131-Monrol acquisition.","breadcrumb":{"@id":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.curiumpharma.com\/de\/2024\/04\/08\/acquisition-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curiumpharma.com\/de\/"},{"@type":"ListItem","position":2,"name":"Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczaciba\u015fi-Monrol"}]},{"@type":"WebSite","@id":"https:\/\/www.curiumpharma.com\/#website","url":"https:\/\/www.curiumpharma.com\/","name":"Curium Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curiumpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Person","@id":"https:\/\/www.curiumpharma.com\/#\/schema\/person\/e4f8faf9cb0b0abf9a175f21afe353c6","name":"Elisabeth Baucells","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/secure.gravatar.com\/avatar\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/33b8a272bd481f1f7e7f35ba80eadfdcbbc3bd405b0dce428b88ffe41082b8c7?s=96&d=mm&r=g","caption":"Elisabeth Baucells"},"url":"https:\/\/www.curiumpharma.com\/de\/author\/elisabeth-baucellscuriumpharma-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/posts\/29654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/users\/89"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/comments?post=29654"}],"version-history":[{"count":0,"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/posts\/29654\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/media?parent=29654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/categories?post=29654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curiumpharma.com\/de\/wp-json\/wp\/v2\/tags?post=29654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}